 |
| |  |
| |  |
| |  |
Axa Framlington has announced the appointment of Andy Smith to their healthcare team. He will take over the
Buy your fund from Hargreaves Lansdown and save up to 5.5% on the initial fund charges. Investment values can go down in value as well as up and you may get back less than the amount you invest. Hargreaves Lansdown Asset Management Ltd. is authorised & regulated by the Financial Services Authority.
Buy Funds Online Now
Popular funds
Initial
savingsBuy fund
First State Investments Greater China Growth
3.75%
Fidelity Sterling Bond
3.00%
Sarasin AgriSar
4.50%
BlackRock UK Absolute Alpha (Class P)
5.00%
Junior Oils CF Junior Oils Trust
4.25%
Andy Smith has worked in the pharmaceutical industry for nearly 30 years with roles including academic research, product development and fund management. He has also successfully managed the International Biotechnology Trust for a venture capitalist firm.
This may prove to be a positive addition to the Axa Framlington healthcare team, but we would like to see how the fund performs under the new manager. We have therefore removed the fund from the Wealth 150 list. We do not believe investors should sell the fund. If we see a pick up in the sector and the manager’s stock picking excels we may consider reinstating the fund to the Wealth 150 list.
» Key Features of the Axa Framlington Biotech Fund
Fund research is provided by Hargreaves Lansdown. Hargreaves Lansdown is an independent broker offering unit trust, stockbroking and other pension and investment services. No news or research item is a personal recommendation to deal.